4
(Adds analyst comments in paragraphs 4, 6-7) Sept 18 (Reuters) – Drug developers Retension Pharmaceuticals and TRex Bio filed their paperwork for U.S. initial public offerings on Friday, reinforcing
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
